Moderna Inc [NASDAQ: MRNA] jumped around 10899974.33 points on Tuesday, while shares priced at $10900000.0 at the close of the session, up 8013048%.
Moderna Inc stock is now -80.06% down from its year-to-date (YTD) trading value. MRNA Stock saw the intraday high of $27.13 and lowest of $26.025 per share. The company’s 52-week high price is 138.07, which means current price is +15.77% above from all time high which was touched on 01/07/25.
Compared to the average trading volume of 10.90M shares, MRNA reached a trading volume of 8013048 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Moderna Inc [MRNA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $43.85 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.86. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citigroup have made an estimate for Moderna Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 13, 2025. While these analysts kept the previous recommendation, Barclays raised their target price from $111 to $45. The new note on the price target was released on February 18, 2025, representing the official price target for Moderna Inc stock. Previously, the target price had yet another drop from $99 to $51, while Goldman kept a Neutral rating on MRNA stock.
The Price to Book ratio for the last quarter was 1.03, with the Price to Cash per share for the same quarter was set at 15.45.
How has MRNA stock performed recently?
Moderna Inc [MRNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.08. With this latest performance, MRNA shares gained by 0.30% in over the last four-week period, additionally sinking by -30.14% over the last 6 months – not to mention a drop of -35.55% in the past year of trading.
Moderna Inc [MRNA]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Moderna Inc [MRNA] shares currently have an operating margin of -117.37% and a Gross Margin at 48.06%. Moderna Inc’s Net Margin is presently recorded at -105.67%.
Return on Equity for this stock declined to -22.81%, with Return on Assets sitting at -22.81%.
Earnings analysis for Moderna Inc [MRNA]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Moderna Inc go to 20.72%.
Insider trade positions for Moderna Inc [MRNA]
There are presently around $73.73%, or 79.52% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: BAILLIE GIFFORD & CO with ownership of 43.45 million shares, which is approximately 11.3149%. VANGUARD GROUP INC, holding 39.56 million shares of the stock with an approximate value of $$4.7 billion in MRNA stocks shares; and VANGUARD GROUP INC, currently with $$3.04 billion in MRNA stock with ownership which is approximately 6.6569%.
